First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis
Jingxin Li, Yijing Tang, Qianying Chen, Sen Lei, Yongkui Lu, Aihua Tan, Weimin Xie · 2024
Read First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis by Jingxin Li, Yijing Tang, Qianying Chen, Sen Lei, Yongkui Lu, Aihua Tan, Weimin Xie (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11688104.txt.
Description
Li and co-authors ask whether a platinum-based drug mix works as first treatment for advanced breast cancer with low levels of the HER2 marker. New targeted drugs help such patients later, but first-line choices were murky. Their 2024 review covers 103 patients with spreading breast cancer who got carboplatin-based treatment first.
Tumors shrank in about forty-three percent of all patients. The rate ran much higher in the low-marker group than in the zero-marker group, at about fifty-six against twenty-seven percent. A blood inflammation ratio also split outcomes, with calmer scores living longer without growth. Youth under forty and a high ratio marked worse outlook. Side effects were mostly low blood counts and were judged tolerable.
Catalog record
| CREATOR | Jingxin Li, Yijing Tang, Qianying Chen, Sen Lei, Yongkui Lu, Aihua Tan, Weimin Xie |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |